Patent Eligibility Bill May Carve Out Patenting Of Research
Executive Summary
Witnesses at US Senate hearings debate bill's impact on drug pricing; discuss limiting it to medical diagnostics.
You may also be interested in...
Supreme Court Takes Pass on Clarifying Patent Eligibility, Disappointing BioPharma
Industry now needs to wait for a more appealing appeal or a revived legislative effort after the high court declines review of Athena Diagnostics v. Mayo Collaborative Services, which created a sharp divide in the Federal Circuit, and Hikma v. Vanda; biopharma and others contend eligibility issue is biggest problem in patent system.
Will Slew of Patent Bills Lower Drug Prices?
Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.
Battle Begins Over Legislation To Expand What Inventions May Be Patented
BIO, PhRMA, AAM, former PTO Commissioners to testify at two-day Senate hearing on draft bill to revise Section 101 of Patent Act; ACLU coalition says legislation will allow patenting of human genes.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
